This image shows Jörn Lausen

Jörn Lausen

Prof. Dr. rer. nat.

Director, Head of Institute
Institute for Biomedical Genetics
Dept. Eukaryote Genetics

Contact

+49 711 685 66971
 +49 711 685 66973

Allmandring 31
70569 Stuttgart
Germany
Room: 1.203-1.205

  1. Schneider, L; Herkt ,S.; Wang L, Feld, C.: Wesely, J.; Kuvardina, ON.; Meyer, A.; Oellerich, T.; Häupl, B.; Seifried, E.; Bonig, H.; Lausen, J.:
    PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1.
    Oncogenesis. 2021 May 17;10(5):42. doi: 10.1038/s41389-021-00332-z.PMID:34001852 

  2. Meyer, A.; Herkt, S.; Kunze-Schumacher, H.; Kohrs, N.; Ringleb, J.; Schneider, L.; Kuvardina, ON.; Oellerich, T.; Häupl, B.; Krueger, A.; Seifried, E.; Bonig, H.; Lausen, J.: The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis.
    Sci Rep. 2020 Dec 8;10(1):21438. doi: 10.1038/s41598-020-78629-z. PMID:33293632 

  3. Roth, H; Schneider, L.; Eberle, R.; Lausen, J.; Modlich, U.; Blümel, J.; Baylis SA.:Zika virus infection studies with CD34+hematopoietic and megakaryocyte-erythroid progenitors, red blood cells and platelets.
    Transfusion. 2020 Mar;60(3):561-574. doi: 10.1111/trf.15692. Epub 2020 Feb 22. PMID: 32086956

  4. Godavarthy, PS.; Kuma, R.; Herkt, SC.; Pereira, RS.; Hayduk, N; Weissenberger, ES.; Aggoune, D.; Manavski, Y.; Lucas, T.; Pan, KT; Voutsinas, JM.; Wu, Q.; Müller, MC.; Saussele, S.; Oellerich, T.; Oehler, VG.; Lausen, J. Krause, DS.: The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.
    Haematologica. 2020 Jan;105(1):136-147. doi:10.3324/haematol.2018.212365. Epub 2019 Apr 24. PMID: 31018977
  1. Windisch, R.; Pirschtat, N.; Kellner, C., Chen-Wichmann, L.; Lausen, J.; Humpe, A.; Krause, DS.; Wichmann, C.:
    Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia.
    Cancers (Basel). 2019 Mar 5;11(3). pii: E311. doi: 10.3390/cancers11030311. Review. PMID:30841639

  2. Chen-Wichmann, L.; Shvartsman, M.; Preiss, C.; Hockings, C.; Windisch, R, Redondo Monte E, Leubolt G, Spiekermann K, Lausen J, Brendel C, Grez M.; Greif, P.A.; Wichmann, C.:
    Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Oncogene. 2019 Jan;38(2):261-272.
  1. Steiner, M.; Schneider, L.; Yillah, J.; Gerlach, K.; Kuvardina, O.N.; Meyer, A.; Maring, A.; Bonig, H.; Seifried, E.; Zörnig, M.; Lausen, J. FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation. PLoS One. 2019 Jan 17;14(1).

  2. Kramer, J.; Désor, V.; Brunst, S.; Wittmann, S.K.; Lausen, J.; Heering, J.; Proschak, A. and Proschak, E.: A coupled fluorescence-based assay for the detection of protein arginine N-methyltransferase 6 (PRMT6) enzymatic activity.
    Anal Biochem. 547: 7-13. 2018 Apr 15
  1. Herkt SC.; Kuvardina, O.N.; Herglotz, J.; Schneider, L.; Meyer, A.; Pommerenke, C.; Salinas-Riester, G.; Seifried, E.; Bonig, H.; Lausen, J.: Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34+ progenitor cells.
    Haematologica. 103(1): 18-29. 2018 Jan

  2. Schanda, J.; Lee, C.W.; Wohlan, K.; Müller-Kuller, U.; Kunkel, H.; Quagliano-Lo Coco, I.; Stein, S.; Metz, A.; Koch, J.; Lausen, J.; Platzbecker, U.; Medyouf, H.; Gohlke, H.; Heuser, M.; Eder, M.; Grez, M.; Scherr, M.; Wichmann, C.:Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.
    Haematologica, 102(5): e170-e174. 2017 May
  1. Kuvardina, O.N.; Herkt, S.; Meyer, A.; Schneider, L.; Yillah, J.; Kohrs, N.; Bonig, H.; Seifried, E.; Müller-Tidow, C.; Lausen, J.: Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression.
    Oncotarget. 8(42): 71685-71698. 2017 Apr 24.
  1. Kohrs, N.; Kolodziej, S.; Kuvardina, O.N.; Herglotz, J.; Yillah, J.; Herkt, S.; Piechatzek, A.; Salinas-Riester, G.; Lingner, T.; Wichmann, C.; Bonig, H.; Seifried, E.; Platzbecker, U.; Medyouf, H.; Grez, M. and Lausen, J.: MiR144/451 expression is repressed by RUNX1 during megakaryopoiesis and disturbed by RUNX1/ETO.
    PLoS Genet.,12(3): e1005946. 2016 Mar 18
  1. Kuvardina, O.N.; Herglotz, J.; Kolodziej, S.; Kohrs, N.; Wojcik, B.; Oellerich, T.; Corso, J.; Behrens, K.; Kumar, A.; Hussong, H.; Urlaub, H; Koch, J.; Serve, H.; Bonig, H.; Stocking, C.; Rieger, M.; Lausen, J.:
    RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.
    Blood, 125(23): 3570-9. 2015 Apr 24.
  1. Ponnusamy, K.; Kohrs, N.; Ptasinska, A.; Assi, S.; Herold, T.; Weigert, O.; Hiddemann, W; Lausen, J.; Bonifer, C.; Henschler, R.; Wichmann, C.: RUNX1/ETO blocks selection binding via transcriptional repression of PSGL-1. Oncogenesis, 4:e146. 2015 April 13.

  2. Müller-Kuller, U.; Ackermann M.; Kolodziej, S.; Brendel, C.; Fritsch, J; Lachmann, N.; Kunkel, H.; Lausen, J.; Schambach, A.; Moritz, T.; Grez, M.:
    A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells.
    Nucleic Acids Research, 18;43(3):1577-92. 2015.
  1. Ponnusamy, K.; Chen-Wichmann, L.; Kuvardina, O.N.; Lausen, J.; Henschler, R.; Wichmann, C.: The truncated Runx1/Eto activates Vla-4-dependent adhesion and migration of hematopoietic progenitor cells.
    Haematologica, 99(12): e253-6. 2014 Dec.
  1. Kolodziej, S.; Kuvardina, O.N.; Oellerich T.; Herglotz, J.; Backert, I.; Kohrs, N.; Buscató, E.; Wittmann, S.K.; Salinas-Riester, G.; Bonig, H.; Karas, M.; Serve, H.; Proschak, E.; Lausen, J.: 
    PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation.
    Nature Communications, 5: 3995. 2014 May 29.

  2. Ng, K.P.; Hu, Z.; Ebrahem, Q.; Negrotto, S.; Lausen, J.; Saunthararajah, Y.: Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.
    Oncogenesis, 2, e78. 2013 Nov 4. W3.
  1. Courtial, N.; Mücke, C.; Herkt, S.; Kolodziej, S.; Hussong H.; Lausen, J.:
    The T-cell oncogene Tal2 is a target of PU.1 and upregulated during osteoclastogenesis.
    PLoS ONE, 8(9): e76637. 2013.

  2. Herglotz, J.; Kuvardina, O.N.; Kolodziej, S.; Kumar, A.; Hussong, H.; Grez, M.; Lausen, J.: Histone arginine methylation keeps RUNX1 target genes in an intermediate state.
    Oncogene, 32(20): 2565-75. 2013 May 16.

  3. Courtial, N.; Smink, J.J.; Kuvardina, O.N.; Leutz, A.; Göthert, J.R.; , J.: Tal1 regulates osteoclast differentiation through suppression of the master regulator of cell fusion DC-STAMP.
    FASEB Journal, 26(2): 523-532. 2012 Feb

  4. Bangert, A.; Cristofanon, S.; Eckhardt, I.; Abhari, B.A.; Kolodziej, S.; Häcker, S.; Vellanki, S.H.K.; Lausen, J.; Debatin, K.M.; Fulda, S.: Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
    Oncogene, 31(44): 4677-88. 2012 Nov 1.
  1. Wichmann, C.; Becker, Y.; Chen-Wichmann, L.; Vogel, V.; Vojtkova, A.; Herglotz, J.; Moore, S.; Koch, J.; Lausen, J.; Mäntele, W.; Gohlke, H.; Grez, M.: Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
    Blood, 116(4): 603-13. 2010 Jul 29.

  2. Lausen, J*.; Pless, O.; Leonard, F.; Kuvardina, O.N.; Koch, B.; Leutz, A.: Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1.
    Chem., 285(8): 5338-46. 2010 Feb.
  1. Pless, O.; Kowenz-Leutz, E.; Knoblich, M.; Lausen, J.; Beyermann, M.; Walsh, M.J.; Leutz, A.: G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta.
    Chem., 283(39): 26357-63, 2008 Sep 26.
  1. Wei, Y.; Liu, S.*; Lausen, J*.; Cho, S.; Biris, N.; Kobayashi, N.; Wei, Y.; Yokoyama, S.; Werner, M.H.: A TAF4-homology domain from the co-repressor Eight Twenty-one (ETO) is a docking platform for positive and negative regulators of transcription. 2007.
    Struct. Mol. Biol., 14(7): 653-661, 2007 Jul. *Equal contr.
  1. Erdmann, S.; Senkel, S.; Arndt, T.; Lucas, B.; Lausen, J.; Klein-Hitpass, L.; Ryffel, G.U.; Thomas, H.: The tissue specific transcription factor HNF4a inhi-bits cell proliferation and induces apoptosis in the pancreatic INS-1 b-cell line. Chem., 388(1): 91-106. 2007 Jan.
  1. Lausen, J.; Liu, S.; Fliegauf, M.; Lubbert, M.; Werner, M.H.:
    ELA2 is regu-lated by hematopoietic transcription factors, but not repressed by AML1-ETO.
    Oncogene, 25(9): 1349-57. 2006 Mar 2.
  1. Lucas, B.; Grigo, K.; Erdmann, S.; Lausen, J.; Klein-Hitpass, L.; Ryffel, G.U.: HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma.
    Oncogene, 24(42): 6418-31. 2005 Sept 22.
  1. Lausen, J.; Cho, S.; Liu, S.; Werner, M.H.: The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO. J.
    Chem., 279 (47): 49281-8. 2004 Nov 19.
  1. Thomas, H.; Badenberg, B.; Bulman, B.; Lemm, I.; Lausen J.; Kind, L.; Roosen, S.; Ellard, S.; Hattersley, A.; Ryffel, G.U.:
    Evidence for haploinsufficiency of the human HNF1a gene by functional characterization of MODY3-associated mutations.
    Chem., 383: 1691-1700, 2002 Nov.
  1. Lausen, J.; Thomas, H.; Lemm, I.; Bulman, M.; Borgschulze, M.; Lingott, A.; Hattersley, A.T.; Ryffel, G.U.:
    Naturally occurring mutations in the human HNF4a gene impair the function of the transcription factor to a varying degree.
    Nucleic Acids Research, 28: 430-437. 2000 Jan 15.
  1. Puzio, P.S.; Lausen, J.; Heinen, P.; Grundler, F.M.W.:
    Promoter analysis of the nematode responsive pyk 20 gene from arabidopsis thaliana.
    Plant Science, 157: 245-255. 2000 Aug 22.
  1. Puzio, P.S.; Lausen, J.; Almeida-Engler, J.; Cai, D.; Gheysen, G.; Grundler, F.M.W.: Isolation of a gene from arabidopsis thaliana related to nematode feeding structures.
    Gene, 239: 163-172, 1999 Oct.18.

 

2001    Ph.D.-thesis, Dissertation

Title: “Einfluss diabetes-assoziierter Mutationen im Transkriptionsfaktor HNF4a“

 

Review Artikel

  1. Windisch, R.; Pirschtat, N; Kellner, C.; Chen-Wichmann, L.; Lausen, J.; Humpe, A.; Krause, DS.; Wichmann, C.:
    Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia.
    Cancers (Basel). 2019 Mar 5;11(3).
  1. Lausen, J.:Contributions of the Histone Arginine Methyltransferase PRMT6 to the Epigenetic Function of RUNX1.
    Rev. Eukaryot Gene Expr., 23(3):265-74. 2013.
  1. Wichmann, C.; Grez, M.; Lausen, J.:
    Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO.
    Current Drug Targets, 11(9): 1181-91. 2010.

 

 

Prof. Dr. rer. nat. habil Jörn Lausen, Diplom-Biologe

CV

01.04.2019                 W3 Professor für Eukaryotengenetik, Universität Stuttgart

2016-2019                  Forschungsgruppenleiter / Projektleiter
                                  DRK-Blutspendedienst Baden-Württemberg/Hessen,
                                  Institut für Transfusionsmedizin und Imunhämatologie der
                                  Goethe Universität Frankfurt                 

10.07.2017                  Habilitation

2008-2016                  Unabhängiger Nachwuchsgruppenleiter / Projektleiter

                                  Institut für Tumorbiologie und experimentelle Therapie, 
                                  Georg-Speyer-Haus, Frankfurt

2005-2008                 Senior-Postdoktorand                   

                                   Max-Delbrück-Center für Molekulare Medizin, Berlin,
                                   Abteilung Zelldifferenzierung und Tumorentstehung,
                                   Prof. Dr. A. Leutz

2001-2005                  Postdoktorand
                                  Rockefeller Universität, New York, USA
                                  Abteilung für molekulare Biophysik, Prof. Dr. M. Werner

2002-2003                 Forschungsstipendium
                                  (Deutsche Forschungsgemeinschaft)

1998-2001                  Doktorarbeit
                                   Universität Essen, Abteilung für Zellbiologie, Prof. Dr. G. Ryffel

2001                           Promotion mit Summa cum laude

1992-1998                  Studium der Biologie
                                  Christian Albrechts Universität, Kiel

1998                           Diplomarbeit
                                   Christian Albrechts Universität, Kiel
                                   Institut für Phytopathologie, Prof. Dr. F. Grundler

1994                           Vordiplom

1998                           Diplom mit sehr gut

To the top of the page